Follow-On Biologics “Integrally Related” To Patent Reform Bill, Sen. Hatch Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Remarks suggest the potential for an alternate vehicle for addressing brand firms’ concerns about patent certainty, even as work on overall health care reform intensifies.
You may also be interested in...
Abbott's Humira Defense May Be Linked To Counter-Suit In Massachusetts
Abbott is looking to the federal appeals court, and a district court in Massachusetts, to shore up its Humira franchise after a Texas jury issued a $1.67 billion verdict against it, finding that the firm's top-selling drug infringes a patent owned by Johnson & Johnson
Abbott's Humira Defense May Be Linked To Counter-Suit In Massachusetts
Abbott is looking to the federal appeals court, and a district court in Massachusetts, to shore up its Humira franchise after a Texas jury issued a $1.67 billion verdict against it, finding that the firm's top-selling drug infringes a patent owned by Johnson & Johnson
Abbott's Humira Defense Hinges On Appeal - And A Countersuit in Massachusetts
J&J awarded $1.67 billion by Texas jury in patent infringement case; Humira is the subject of three other suits.